Study | Country | Criteria for IBS | Sample size (ramosetron vs placebo) | Dose | Treatment duration | Follow-up duration | Primary outcomes | Secondary outcomes |
---|---|---|---|---|---|---|---|---|
Matsueda K 2008a [25] | Japan | Rome II | 270 vs 269 | 5 μg | 12 weeks | 12 weeks | Relief of overall IBS symptoms | 1.Relief of abdominal discomfort/pain 2.Improvement in abnormal bowel habits 3.Assessment of IBS symptomsa |
Matsueda K 2008b [26] | Japan | Rome II | 103 vs 109 | 5 μg | 12 weeks | 12 weeks | Relief of overall IBS symptoms | 1.Relief of abdominal discomfort/pain 2.Improvement in abnormal bowel habits 3.Assessment of IBS symptomsa |
Fukudo S 2014 [22] | Japan | Rome III | 147 vs 149 | 5 μg | 12 weeks | 12 weeks | Improvement in stool consistency | 1.Relief of overall IBS symptoms 2.Relief of abdominal discomfort/pain 3.Improvement in abnormal bowel habits 4.Assessment of IBS symptomsa 5.IBS-QOL |
Fukudo S 2015 [23] | Japan | Rome III | 292 vs 284 | 2.5 μg | 12 weeks | 12 weeks | 1.Relief of overall IBS symptoms 2.Improvement in stool consistency | 1.Relief of abdominal discomfort/pain 2.Improvement in abnormal bowel habits 3.Assessment of IBS symptomsa 4.IBS-QOL |